| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3295772 | Gastroenterology | 2010 | 16 Pages |
Abstract
Monoclonal antibodies against the HCV entry factor CLDN1 might be used to prevent HCV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.
Keywords
CLDNCell culture-derived HCVHCVccHCVppCMFDAPHHIC50CTRLMFIGenetic barrierHA-tagIgGmAbHCV pseudoparticles3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide50% inhibitory concentrationprimary human hepatocytesMTTMonoclonal antibodyTight junctionimmunoglobulin GDissociation constantTreatmentAntiviralHost factormean fluorescence intensityHepatitis C virusHCVclaudinControlReceptor
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Isabel Fofana, Sophie E. Krieger, Fritz Grunert, Sandra Glauben, Fei Xiao, Samira Fafi-Kremer, Eric Soulier, Cathy Royer, Christine Thumann, Christopher J. Mee, Jane A. McKeating, Tatjana Dragic, Patrick Pessaux, Francoise Stoll-Keller,